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with receptor binding IL-1a and IL-b and there are nine IL-1 receptors widely distrib-
uted in tissues. Polymorphisms in cytokines has been described to associated with
different pathologies and some of them have been correlated with enhance or dimin-
ished the production of this molecules. The aim of this study is to determinate the
association between polymorphisms in genes of the family members of the IL-1
and cervical cancer. Polymorphisms of IL-1a -889 C/T, IL-b -511 C/T, +3962 T/C, IL-
1R Pstl1970 C/T and IL-1RA mspa1 11100 was determinate in 19 healthy women
and in 50 women with cervical cancer from the Occident of Mexico. We found statis-
tical differences in IL-1a -889 C/T, with a higher frequency of the allele T in cervical
cancer women compared with healthy controls, with a p = 0.0199, and OR of 4.099
and CI 95% 1.161-14.47; beside we found the CC genotype predominantly in healthy
women p = 0.0255 and CT genotype with p = 0.0481 than women with cervical cancer.
We did not found statistical differences in the others polymorphisms. The T allele of
IL-1 -889 has been implicated in the increase of the expression and production of this
cytokine in different studies and could participate in the chronic inﬂammation that
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Recruitment of effector T cells to sites of infection is imperative for an effective
adaptive immune response. The inﬂammatory chemokine CCL5/RANTES activates
its cognate receptor, CCR5, to initiate a number of cellular functions, including prolif-
eration, chemotaxis, cytokine production, and apoptosis. We have shown that CCL5/
CCR5 signaling activates the mTOR/4E-BP1 pathway to directly modulate mRNA
translation. Moreover, CCL5-mediated mTOR activation inﬂuences T cell chemotaxis
by initiating the translation of chemotaxis-related proteins, including MMP-9 and
cyclin D1. Up-regulation of chemotaxis-related proteins may ‘‘prime” T cells for efﬁ-
cient migration. It is now clear that mTOR is a central regulator of cell size, nutrient
sensing and glycolysis. In continuing studies, we are investigating the ability of CCL5
to regulate T cell metabolism through the PI-30K/mTOR pathway. Data generated in
ex vivo activated human T cells show that CCL5 treatment, at doses that invoke che-
motaxis, induces the activation of nutrient sensing kinase AMPK and key glycolytic
metabolites including GSK-3b. This suggests that CCL5 may be up-regulating ATP-
consuming pathways and modulating glycolysis. Flow cytometry data show that
CCL5 is also able to up-regulate the expression of amino acid transporter CD98, while
having no effects on glucose transporter, Glut-1. In addition, using a radio-labelled
glucose, we provide evidence for glucose uptake mediated by CCL5 treatment. Finally,
inhibition studies with a glucose analogue, 2-deoxy-D-glucose, we demonstrate
reduced CCL5-mediated T cell chemotaxis in a dose-dependent manner. Viewed alto-
gether, these ﬁndings suggest that CCL5, at concentrations that support optimal che-
motaxis, may also inﬂuence the metabolic status of activated T cells.
doi:10.1016/j.cyto.2010.07.403
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Cytokines are naturally occurring small regulatory proteins produced by various
cell types. They act as external controlling elements in haematopoiesis and also medi-
ate and control immune and inﬂammatory responses. Changes in cytokine levels have
been reported in chronic obstructive pulmonary disease (COPD), a common inﬂam-
matory disease of the airways. Similarly, changes in circulating cytokine levels have
been reported in other pulmonary disorders including lung cancer, but the speciﬁc
nature of these changes is poorly deﬁned. Because cytokines normally function as part
of a complex interacting network, the use of a multiplexed approach for their deter-
mination is important. Biochip array technology enables such an approach and can
generate a cytokine proﬁle from a single sample, at a single point in time. The aim
of this study was to determine twelve cytokines simultaneously in the plasma of
non-smokers and smokers with or without COPD and with or without lung cancer
using Evidence biochip array technology. The cytokines IL-1a, IL-1b, IL-2, IL-4, IL-6,
IL-8, IL-10, VEGF, IFNc, EGF, MCP-1 and TNFawere quantiﬁed by simultaneous chemi-
luminescent immunoassays on the biochip array. The biochip represents the solid-
phase and the vessel where the immunoreactions take place in discrete test sites.
The Evidence analyzer was used for all determinations. Serum samples from 55
non-smokers, 54 smokers without COPD and 48 smokers with COPD were analyzed.
The Kruskal-Wallis test with a false discovery rate (FDR) of 0.10 was used to identify
cytokines that were differentially expressed across the 5 groups. For the cytokines
that met the FDR criterion, post-hoc comparisons were made using Dunn’s method
with a family-wise error rate 0f 0.05.
Four cytokines appeared to be differentially expressed across groups: IL-6, IL-8,
VEGF and MCP1. Results of the post-hoc pairwise comparisons suggest plasma cyto-
kine levels are signiﬁcantly different between the following groups: non-smokers vs.
adenocarcinoma (IL-6, IL-8); non-smokers vs. squamous cell cancer (IL-6, IL-8, VEGF);
non-smokers vs. smokers with COPD (MCP1); smokers without COPD vs. adenocarci-
noma (IL-6); smokers with COPD vs. squamous cell carcinoma (IL-6); smokers with-
out COPD vs. squamous cell carcinoma (IL-6, IL-8, VEGF) and adenocarcinoma vs.
squamous cell carcinoma (VEGF, IL-8). The biochip array enables the simultaneous
assessment of 12 cytokines in a single sample and shows differences between several
distinct clinical groups. This represents a valuable analytical approach for research in
conditions involving the cytokines.
doi:10.1016/j.cyto.2010.07.404
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MilliplexTM MAP multiplex immunoassays for simultaneous detection of human
and mouse cytokines/chemokines
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Cytokine and chemokines are soluble proteins that exert a number of biological
functions in both normal conditions and disease states such as metabolic disease,
arthritis, sepsis, and cancer. Using Luminex’s xMAP technology, we previously devel-
oped and commercialized the MILLIPLEX MAP Human Cytokine/Chemokine 42-plex
Panel and Mouse Cytokine/Chemokine 32-plex panel, which allow the simultaneous
measurement of 42 human cytokines or 32 mouse cytokines with minimal require-
ment of sample volume (12.5ll-25ll). Recently, we expanded our cytokine/chemo-
kine portfolio with two new Human Cytokine Panels (Panel II: 23-plex; Pane III:
11-plex) and two new Mouse Cytokine Panels (Panel II: 12-plex; Panel III: 6-plex).
Brieﬂy, 25 ll of neat (human) or 1:2 diluted (mouse) serum/plasma sample was incu-
bated overnight at 4C in a 96-well ﬁlter plate with a mixed population of Luminex
beads, each of which contains a unique ﬂuorescent signature and covalently coupled
with a speciﬁc capture antibody. After washing, the plate was incubated with 25 ll
biotinylated detection antibodies for 1 h and, subsequently, with 25 ll streptavi-
din-phycoerythrin solution for 30 min at RT. Fluorescent signal of the beads was read
using a Luminex 200 reader. Sample concentrations were calculated with 5-parame-
ter logistic curve-ﬁtting method. The analytical robustness of these assays is demon-
strated by high accuracy (spike-recovery: 96–111%) and good precision (intra-assay
CV: <10%; inter-assay CV: <16%).These new MILLIPLEX MAP panels are highly sensitive
and display no signiﬁcant cross-reactivity within each panel. In addition, the assays
were validated in normal serum/plasma, sepsis serum, and LPS-challenged PBMC tis-
sue culture supernatant samples. In summary, our MILLIPLEX MAP cytokine multiplex
assays are speciﬁc, accurate, reproducible and user-friendly. The availability of these
assays provides useful tools for the investigation of biological functions of cytokines/
chemokines in various diseases.
doi:10.1016/j.cyto.2010.07.405
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The need for both high throughput immunoassays and immunoassays which can
measure broad ranges of analyte is increasing. Traditionally, immunoassays must be
built to focus on either sensitivity or the ability to quantify high analyte concentra-
tions. Rarely have there been assays which can achieve high sensitivity while main-
taining the ability to quantify high analyte concentrations. Faced with these
limitations, researchers have had to test multiple dilutions of their sample to ensure
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